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We previously showed that the retinoblastoma protein (pRB), a key regulator of G1 to S-phase transition of the cell cycle, binds to and
stimulates diacylglycerol kinase-ζ (DGKζ) to phosphorylate the lipid second messenger diacylglycerol into phosphatidic acid. pRB binds to the
MARCKS phosphorylation-site domain of DGKζ that can be phosphorylated by protein kinase C (PKC). Here, we report that activation of PKC
by phorbol ester inhibits DGKζ binding to pRB. Ro 31-8220, a specific inhibitor of PKC, alleviated this inhibition of binding. Mimicking of PKC
phosphorylation of serine residues (by S/D but not S/N mutations) within the DGKζ-MARCKS phosphorylation-site domain also prevented
DGKζ binding to pRB, suggesting that PKC phosphorylation of these residues negatively regulates the interaction between DGKζ and pRB. In
PKC overexpression studies, it appeared that activation of particularly the (wild-type) PKCα isoform inhibits DGKζ binding to pRB, whereas
dominant-negative PKCα neutralized this inhibition. PKCα activation thus prevents DGKζ regulation by pRB, which may have implications for
nuclear diacylglycerol and phosphatidic acid levels during the cell cycle.
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The second messenger diacylglycerol (DAG) participates via
its targets, including PKC, Ras-GRP, chimaerins, and Munc-13,
in the regulation of several cellular processes, such as
proliferation, differentiation and cell migration [1]. Several
growth factors stimulate DAG production by activating
phospholipase C, which hydrolyses phosphatidylinositol 4,5-
bisphosphate. DAG is not only present at the plasma membraneAbbreviations: DAG, diacylglycerol; DGK, diacylglycerol kinase; GST,
glutathion-S-transferase; MARCKS, myristoylated alanine-rich C-kinase sub-
strate; PSD, phosphorylation-site domain; PKC, protein kinase C; pRB,
retinoblastoma protein
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doi:10.1016/j.bbamcr.2006.12.004but also in the nucleus where it can also be generated by a
nuclear phospholipase C [2] that is activated independently
from a cytosolic phospholipase C [3], suggesting that nuclear
DAG has distinct functions.
Awell-characterised target of DAG is PKC. The PKC family
consists of ten different isoforms, of which only the conven-
tional (α, βI, βII and γ) and novel (δ, -ε, -η, and -θ) PKC
isoforms respond to DAG (or phorbol ester) [4]. One poorly
defined function of PKC relates to the cell cycle. Depending on
the cell system, PKC isoform, and the timing of PKC activation
within the cell cycle, PKC can stimulate or inhibit the cell cycle
[reviewed in ref. 5]. PKC regulates phosphorylation of the
retinoblastoma-family of pocket proteins (pRB, p107 or p130),
which regulate G1 to S-phase transition and cell cycle entry and
exit by sequestering and inactivating the E2F family of
transcription factors [6,7]. In addition, PKCβ2 was found to
directly phosphorylate pRB in retinal endothelial cells, causing
E2F release and proliferation [8]. In many cell types, PKC
induces the expression of p21WAF/CIP1, a cyclin/CDK inhibitor
Fig. 1. DGKζ binding to pRB is inhibited by PKC activation. (A) COS-7 cells
overexpressing DGKζ were stimulated with PMA (100 nM; 20 min) or its
inactive analogue 4α-PDD. Cell lysates were subjected to affinity-purifications
using GST-pRB or GST-Cdc42 (as a control). DGKζ binding to GST fusion
proteins was assessed by Western blotting using a DGKζ-specific antibody (left
panel). Total cell lysates were immunoprobed using a DGKζ specific antibody
to demonstrate equal expression (right panel). (B) COS-7 cells overexpressing
DGKζ were pretreated with Ro 31-8220 (5 μM) or vehicle for 20 min prior to
PMA stimulation. Lysates were assayed for DGKζ binding to GST-pRB or
GST-pRB(A+B). Data are representatives of three experiments with similar
results.
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cycle arrest [reviewed in ref. 5].
Since DAG activates PKCs, its subcellular levels need to be
tightly controlled. One mechanism by which this can be
achieved is through diacylglycerol kinases that phosphorylate
DAG into phosphatidic acid. Ten different DGK isoforms have
been identified that act in different signal transduction pathways
[9,10]. One isoform, DGKζ, is characterized by a domain
homologous to the PKC phosphorylation-site domain (PSD)
within the myristoylated alanine-rich C-kinase substrate
(MARCKS) protein (MARCKS-PSD). The DGKζ-MARCKS-
PSD contains a nuclear localisation signal and was shown to be
phosphorylated by PKCα [11–13].
Although DGKs are thought to attenuate PKC activation,
regulation of PKCα activity by DGKζ is more complicated
since these two enzymes interact and regulate each others
activity. Under basal conditions, DGKζ binds to and inhibits
PKCα activity [14], but upon activation of PKCα, the
interaction with DGKζ is disrupted. PKCα, in turn, phosphor-
ylates DGKζ, which causes nuclear export and inhibition of
DGKζ activity [12,13]. These feed-back/feed-forward mechan-
isms allow tight regulation of DAG levels as well as DGKζ and
PKCα activity.
We previously found that DGKζ binds to pRB and that the
DGKζ-MARCKS-PSD is sufficient for pRB binding [15].
Since PKC phosphorylates the DGKζ-MARCKS-PSD, we
questioned whether PKC-mediated phosphorylation of DGKζ
might regulate DGKζ binding to pRB. In this study we show
that this is indeed the case. We show that PMA pre-treatment
decreases the interaction between DGKζ and pRB and that this
is attenuated by pre-treatment with the PKC inhibitor Ro 31-
8220. Mutation of critical serine residues within the DGKζ-
MARCKS-PSD, previously shown to be phosphorylated by
PKC, to aspartate which mimics phosphorylation, inhibits
DGKζ binding to pRB. Finally, using overexpression of
different PKC isofoms, we provide evidence that PKCα is the
isoform that is involved in regulating the interaction between
DGKζ and pRB. Our data suggests that PKC mediated
phosphorylation of the DGKζ-MARCKS-PSD not only leads
to nuclear exit [12], but also to a decrease in the nuclear DGKζ
activity by inhibiting its interaction with pRB, a potent
stimulator of DGKζ activity.
2. Materials and methods
2.1. Materials, cells, plasmids and transfection
Dulbecco's modified Eagle's medium (DMEM) was from Invitrogen. [32P]
orthophosphate was from Amersham Biosciences. Ro 31-8220 was from
Calbiochem. PMA and 4α-phorbol-12,13-didecanoate (4α-PDD) were obtained
from Sigma. COS-7 andMCF7 cells were grown in DMEM containing 8% heat-
inactivated fetal calf serum, 2 mM glutamine and antibiotics. COS-7 cells were
transfected using the DEAE-dextran method or TransIT-LT1 Transfection
Reagent (Mirus) according to manufacturer's instructions. Wild-type- and
FLAG-tagged DGKζ, as well as the DGKζ-MARCKS-PSD mutants, in which
serines (Ser258, Ser265, Ser270 and Ser271) were mutated to asparagines (S/N) or
aspartates (S/D) (see Fig. 2A) were generated as described previously
[12,13,16]. Human PKC isotypes, including PKCα and its dominant-negative
version (dnPKCα), in which a lysine in the ATP-binding site was replaced by an
aspartate (K368D), were subcloned into pcDNA3 plasmid (Invitrogen).2.2. Cellular lysates and affinity-purifications
48 Hours after transfection, cells were lysed in 1%NP40 lysis buffer (50 mM
Tris, pH 8.0; 50 mMKCl; 10 mM EDTA; 1% NP40; complete protease inhibitor
cocktail (Roche)). Affinity purifications were performed using the following
GST fusion proteins: GST-pRB, consisting of the large pocket region of pRB that
includes the small pocket domain and the C-terminus, GST-pRB(A+B),
consisting of the small pocket domain of pRB, and GST-Cdc42. GST fusion
proteins were expressed in bacteria and, after induction with 200 μM IPTG,
were purified using glutathione-sepharose 4B beads (Amersham) according to
manufacturer's instructions. Approximately 4 μg of immobilized GST fusion
proteins were incubated with 200 μg of cell lysate for 2 h at 4 °C and washed
with 1% NP40 lysis buffer. All samples within an assay contained the same
amount of beads. For peptide competition assays, 1 or 10 μg of peptide was
incubated together with COS-7 lysate and GST-pRB. Affinity-purified proteins
were separated by SDS-PAGE, transferred to nitrocellulose and probed with an
anti-DGKζ polyclonal antibody [16]. Blots were stained with secondary
antibodies (DAKO) and visualised using ECL (Amersham) or Super Signal
(Pierce).
For peptide affinity-purifications, 100 μg of biotinylated TAT-DGKζ-
MARCKS-PSD peptides (wt: YARAAARQARAGKASKKKKRASFK-
RKSSKK, S/D: YARAAARQARAGKADKKKKRADFKRKDDKK, or S/N:
YARAAARQARAGKANKKKKRANFKRKNNKK) or TAT control peptide
(YARAAARQARAG) were incubated overnight with MCF7 lysate (450 μg
protein). Peptides were captured on streptavidin agarose (Sigma) and washed
with wash buffer (50 mM Tris pH 7.4, 140 mM NaCl, 10 mM MgCl2, 0.1%
Tween-20). Associated pRB was visualised by immunoblotting using anti-pRB
monoclonal antibody G3-245 (Pharmingen).
2.3. In vivo phosphorylation
Transfected COS-7 cells were serum-starved overnight and incubated for 2 h
with phosphate-depleted DMEM containing 250 μCi [32P] orthophosphate per
6 cm dish. Cells were maintained as controls or were stimulated with PMA
(100 nM) for 20 min. Cells were lysed in 1%NP40 buffer including protease and
phosphatase inhibitors and FLAG-DGKζ was immunoprecipitated overnight
using monoclonal anti-FLAG M2 antibody (Sigma). Antibodies were captured
on protein G-Sepharose beads (Amersham) and washed with 1% NP40 lysis
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SDS-PAGE, transferred onto nitrocellulose membranes, and [32P] phosphory-
lated proteins were analysed by autoradiography. Blots were stained with a
FLAG-specific antibody to detect total DGKζ.
3. Results
3.1. Activation of PKC inhibits DGKζ binding to pRB
Since the DGKζ-MARCKS-PSD was shown to be phos-
phorylated by PKC and we have shown that the retinoblastoma
gene product (pRB) binds to the DGKζ-MARCKS-PSD, we
assessed the role of phosphorylation on the interaction between
pRB and DGKζ. COS-7 cells overexpressing DGKζ wereFig. 2. DGKζ binding to pRB is inhibited by phosphorylation site mimics of
serine residues within the MARCKS-phosphorylation-site domain of DGKζ.
(A) Schematic representation of DGKζ and the DGKζ-MARCKS-PSD mutants.
Substituted residues are indicated in bold. (B) COS-7 cells were transfected with
wild-type DGKζ (wt-DGKζ) or DGKζ-MARCKS-PSD S/D or S/N point-
mutants and were stimulated with (+) or without (−) PMA (100 nM; 20 min).
Cell lysates were used for affinity-purification of DGKζ using equal amounts of
GST-pRB or GST-Cdc42 as a negative control. Affinity-purified DGKζ was
analysed by Western blotting using a DGKζ-specific antibody (upper panel),
and quantified relative to wt-DGKζ (non-stimulated control; set at 100%)
(bottom panel). Black bars, non-stimulated; gray bars, PMA-stimulated. Total
cell lysates were immunoprobed using a DGKζ-specific antibody to demonstrate
equal expression (middle panel).
Fig. 3. S/D-DGKζ-MARCKS-PSD peptide has reduced affinity for pRB. (A)
Biotinylated wild-type-, S/D- or S/N mutant DGKζ-MARCKS-PSD peptides
were incubated with MCF7 cell lysate for 16 h. Peptides were immobilised on
streptavidin agarose beads and extracted proteins were separated by SDS-PAGE,
transferred to nitrocellulose and stained for pRB using a pRB-specific antibody.
(B) S/D-DGKζ-MARCKS-PSD mutant peptide has reduced capacity to
compete with full-length DGKζ for GST-pRB binding. Lysates of COS-7
cells overexpressing DGKζ were incubated for 2 h with 1 or 10 μg of indicated
peptides together with GST-pRB immobilized on glutathione-sepharose 4B
beads. Affinity-purified DGKζ was visualised by immunoblotting using an anti-
DGKζ antibody.treated with the phorbol ester 12-O-tetradecanoylphorbol-13-
acetate (PMA) to activate PKC and lysates were used for
affinity-purifications using GST-pRB or GST-Cdc42 as a
control. In untreated cells, a substantial amount of DGKζ
bound to GST-pRB, whereas GST-pRB extracted less DGKζ
from cells pre-treated with PMA (Fig. 1A). DGKζ binding to
pRB was not affected when cells were treated with the inactive
phorbol ester analogue 4α-phorbol-12,13-didecanoate (4α-
PDD). These results suggest that activation of PKC by (active)
phorbol ester inhibits DGKζ binding to pRB.
To implicate PKC activity in PMA-mediated regulation of
the interaction between DGKζ and pRB, we pre-treated COS-7
cells overexpressing DGKζ with Ro 31-8220, a specific PKC
inhibitor, prior to PMA treatment. Pre-treatment with Ro-31-
8220 completely rescued the PMA-mediated inhibition of
DGKζ binding to pRB (Fig. 1B), indicating that PMA-mediated
activation of PKC regulates DGKζ binding to pRB. As a
control, DGKζ shows weak or no binding to the small pocket
region (A+B) of pRB (Fig. 1B), like we described previously
[15].
3.2. Mimicking of PKC-mediated phosphorylation of serine
residues in the DGKζ-MARCKS-PSD by S/D mutations inhibits
binding of DGKζ to pRB
To investigate whether PKC-specific serine phosphorylation
sites in the DGKζ-MARCKS-PSD are involved in regulating
DGKζ binding to pRB, we used DGKζ-MARCKS-PSD
Fig. 4. PKC activation inhibits the interaction between DGKζ and pRB. (A)
COS-7 cells were co-transfected with DGKζ and PKC isoforms indicated and
stimulated for 20 min with PMA (100 nM). Lysates were used to affinity-purify
DGKζ using GST-pRB or GST-pRB(A+B) as a control. Affinity-purified
DGKζ was visualised by Western blotting using a DGKζ-specific antibody (left
panel). Total cell lysates were immunoprobed for DGKζ and PKC isotypes to
demonstrate equal expression in the various lysates. (B) Histogram showing the
relative amounts of DGKζ bound to pRB. Data are means±S.E.M. of six
independent experiments. (*) represents the significantly enhanced PMA-
induced inhibition of DGKζ binding by PKCα overexpression (p<0.05), as
determined by analysis of variance.
Fig. 5. Dominant-negative PKCα counteracts the PMA-induced inhibition of
DGKζ binding to pRB. COS-7 cells were co-transfected with DGKζ and wild-
type PKCα or dominant-negative (dn)PKCα, where indicated, and stimulated
for 20 min with PMA (100 nM), where indicated. Cell lysates were used to
affinity-purify DGKζ using GST-pRB or GST-Cdc42 as a control. Equal
amounts of the GST-fusion proteins were used, as shown in the Western blots.
Affinity-purified DGKζ was visualised by Western blotting using a DGKζ-
specific antibody (upper panel). Total cell lysates were immunoprobed for
DGKζ and PKCα content (middle panel). The histogram (lower panel)
represents a quantification of GST-pRB-bound DGKζ protein levels of the upper
panel. It depicts the ratios (in %) of the amount of DGKζ bound with/without
PMA stimulation in control cells and in cells overexpressing PKCα or dnPKCα.
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substitution, S/D) or cannot be phosphorylated (serine to
asparagine substitution, S/N) (Fig. 2A). Wild-type DGKζ and
both types of serine mutants were overexpressed in COS-7 cells
and lysates were used for affinity-purification using GST-pRB
fusion proteins. Whereas wild-type- and S/N-DGKζ bound to
GST-pRB, binding of S/D-DGKζ to pRB was impaired (Fig.
2B), suggesting that, indeed, phosphorylation of serines in the
DGKζ-MARCKS-PSD inhibits the interaction between DGKζ
and pRB. Treatment of cells with PMA reduced the pRB
binding of wild-type DGKζ (like in Fig. 1) to the level of (non-
treated) S/D-DGKζ. Furthermore, PMA reduced the binding of
wild-type DGKζ more than S/N-DGKζ (Fig. 2B), in agreement
with the lack of PKC-mediated phosphorylation at these S/N
mutation sites. We note, however, that TPA further reduced the
binding of S/D-DGKζ and S/N-DGKζ mutants to GST-pRB
(Fig. 2B), suggesting that other phosphorylation sites within
DGKζ or pRB are also involved in the negative regulation of
DGKζ binding to pRB by PKC.We previously used a DGKζ-MARCKS-PSD peptide to
extract pRB from MCF7 cells [15]. Here, we tested whether
biotinylated DGKζ-MARCKS-PSD peptides containing the S/
D or S/N substitutions would be capable of binding to pRB.
Like the wild-type peptide, the S/N mutant peptide was capable
of extracting pRB from MCF7 cells, whereas pRB binding to
the S/D mutant peptide was impaired (Fig. 3A). Furthermore,
both wild-type- and S/N mutant peptides could compete with
full-length DGKζ for pRB binding (Fig. 3B, lanes 5 and 7),
whereas the S/D peptide competed less efficiently (lane 6). All
together, these results indicate that mimicking of PKC-mediated
phosphorylation of the DGKζ-MARCKS-PSD reduces DGKζ
binding to pRB.
3.3. PKCα is the preferred isozyme involved in inhibition of
DGKζ binding to pRB
To determine which PKC regulates the interaction between
DGKζ and pRB, we co-expressed DGKζ with different PKC
isoforms (α,β1, β2, δ, ε) in COS-7 cells, stimulated PKC
activity by PMA, and performed affinity-purifications using
Fig. 6. DGKζ is phosphorylated by PKC (PKCα). COS-7 cells were transfected
with FLAG-DGKζ and/or PKCα (as indicated) and incubated with [32P]
orthophosphate for 3 h. Cells were kept as controls, or were stimulated with
PMA (100 nM) for 20 min, as indicated. FLAG-DGKζ was immunoprecipitated
using a FLAG-specific antibody and immunoprecipitated proteins were
separated by SDS-PAGE and transferred to nitrocellulose. Radiolabelled
DGKζ was visualised by autoradiography (upper panel). Total DGKζ was
visualised using a FLAG-specific antibody (lower panel).
Fig. 7. Model for the PKC-mediated regulation of DGKζ binding to pRB. Under
basal conditions, DGKζ binds to pRB and stimulates DGKζ activity to keep
DAG levels low and PKC (PKCα) inactive. Growth factor-induced DAG
formation in the nucleus or addition of PMA activates PKC that now
phosphorylates DGKζ on serines in the DGKζ-MARCKS-PSD. This phosphor-
ylation disrupts the interaction between DGKζ and pRB, inhibits DGKζ activity
and leads to DGKζ exit from the nucleus [12].
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ments, DGKζ binding to pRB was inhibited when cells were
treated with PMA (Figs. 4A and B). However, when PKCα was
co-expressed with DGKζ, a further (significant) inhibition of
binding of DGKζ to pRB was found. The other PKC isoforms
(of which only β1 is included in Fig. 4) did not significantly
enhance the PMA-induced inhibition of DGKζ binding to pRB .
This result suggests that activation of PKCα in particular can
regulate the interaction between DGKζ and pRB. To support
this notion, we show in Fig. 5 that transfection of a kinase-
inactive, dominant-negative PKCα (K368D) counteracts the
PMA-induced inhibition of DGKζ binding to GST-pRB.
To demonstrate that DGKζ is phosphorylated in vivo by
PKCα, COS-7 cells were transfected with DGKζ, incubated
with [32P] orthophosphate to label the ATP pool, and then
stimulated with PMA. Unstimulated cells showed basal levels
of DGKζ phosphorylation, which was increased 2-fold upon
stimulation with PMA (Fig. 6, lanes 1 and 2). In cells that co-
expressed PKCα, PMA treatment further enhanced the
phosphorylation of DGKζ by 1.6-fold compared to PMA
alone (Fig. 6, upper panel, lanes 2 and 3). These results indicate
that DGKζ is phosphorylated by PKCα in vivo.
4. Discussion
The present study demonstrates that the direct physical
interaction between pRB and DGKζ is regulated by PKC,
particularly PKCα. Activation of PKC by PMA inhibits DGKζ
binding to pRB, and this inhibition could be prevented by
transfection of dominant-negative PKCα or by preincubation
with a PKC-specific inhibitor. Furthermore, we have shown that
phosphorylation of serine residues in the DGKζ-MARCKS-
PSD is sufficient for inhibiting DGKζ binding to pRB,
suggesting that PKCα disrupts the interaction between pRB
and DGKζ by phosphorylating the DGKζ-MARCKS-PSD. The
conclusions and some physiological implications of our results
are summarised in the cartoon depicted in Fig. 7.
In addition to the regulation of DGKζ binding to pRB,
PKCα-mediated phosphorylation of the DGKζ-MARCKS-PSDhas also been shown to disrupt binding of PKCα to DGKζ, even
though the catalytic domain of DGKζ is the PKCα binding site
[14]. In N1E-115 neuroblastoma cells, phosphorylation of the
DGKζ-MARCKS-PSD was shown to negatively regulate Rac1
binding to the C1 domain of DGKζ [17]. Furthermore, in COS-
7 cells, Jurkat T-cells, C2 myoblasts and N1E-115 neuroblas-
toma cells, phosphorylation of the DGKζ-MARCKS-PSD
regulates DGKζ localisation [12,17–19]. Thus, DGKζ-
MARCKS-PSD phosphorylation appears to be a general way
of regulating DGKζ functioning.
PKCα-mediated regulation of DGKζ binding to pRB adds a
new level of complexity by which PKCα and DGKζ regulate
each others activity. We have previously shown that pRB
binding to DGKζ stimulates DGKζ activity [15]. Since
phosphorylation of DGKζ by PKCα causes nuclear export of
DGKζ [12], it seems likely that this export is facilitated by the
PKCα-mediated dissociation of the DGKζ-pRB complex,
leaving ‘free’ pRB in the nucleus (Fig. 7). With this
dissociation, PKCα at the same time inhibits pRB activation
of DGKζ in the nucleus. Since DGKζ activity can furthermore
be inhibited upon phosphorylation by PKCα [13], it can be
concluded that pRB and PKCα have opposing effects on DGKζ
activity.
Regulation of DGKζ activity by pRB and PKCα in the
nucleus supposedly affects nuclear DAG levels. Since DGKζ
binds to the hypophosphorylated form of pRB [15], we
hypothesise that DGKζ keeps nuclear DAG levels low during
the G1 phase of the cell cycle and in quiescent cells. When PKC
becomes activated, it phosphorylates DGKζ and inhibits
binding of DGKζ to pRB. Thereby, DGKζ becomes less active
and is exported from the nucleus, causing nuclear DAG levels to
increase (Fig. 7). Increased nuclear DAG levels may further
activate PKC or recruit more PKCα to the nucleus. This feed-
forward mechanism might contribute to cell cycle regulation. In
accordance with this hypothesis, stimulation of Swiss 3T3 cells
with IGF-1 caused an increase in nuclear DAG levels, which
recruited PKCα to the nucleus and increased the number of cells
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nuclear DAG levels decrease in MEL cells that were stimulated
to terminally differentiate [2,21], whereas artificially increasing
nuclear DAG levels (by overexpression of nuclear PLCβ)
inhibits MEL cell differentiation [22].
How PKC activation contributes to cell cycle progression
needs to be further investigated. PKC can positively regulate
proliferation by regulating enzymes involved in DNA synth-
esis and nuclear structure, including DNA-polymerase β,
topoisomerase, lamins, and histones [23–26]. In contrast,
however, PKC isoforms, including PKCα, can negatively
regulate S-phase entry by inhibiting expression of cyclins and
CDKs and by induction of p21WAF/CIP1 causing hypopho-
sphorylation of pRB and cell cycle arrest [5,27]. Furthermore,
depending on the timing of PKC activation during G1, cell
proliferation can be stimulated or inhibited [28]. We suggest
that positive and negative regulation of DGKζ by pRB and
PKC respectively are likely to be important in the spatio-
temporal modulation of nuclear DAG levels which in turn may
be involved in regulating aspects of cell cycle progression.
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